Dr. Priya Sharma
Managing PartnerManaging Partner and co-founder of Basil Health Ventures since 2014, leading the fund's digital health and diagnostics practice. Board seats on six portfolio companies. Dr. Sharma evaluates clinical evidence personally — not through consultants — and that standard shapes how the entire firm assesses deals. Previously an attending cardiologist at MGH for eight years. MD/PhD, Harvard Medical School.
James Okafor
General PartnerGeneral Partner at Basil Health Ventures, leading the fund's medical device and medtech investments. James brings operator-level commercial instincts to device deals — board member at four portfolio companies, with deep knowledge of hospital procurement, reimbursement pathways, and device commercialization. Previously VP of Corporate Strategy at Medtronic, leading M&A and new-business development across the cardiac and vascular portfolio. MBA, Wharton.
Dr. Sarah Chen
PartnerPartner at Basil Health Ventures leading the biotech thesis — gene therapy, precision oncology, and novel modalities. Dr. Chen evaluates scientific diligence from first principles: she has run the experiments herself. Board observer at three portfolio companies in gene editing and computational drug discovery. Previously a postdoctoral researcher at the Broad Institute working on large-scale genomic analysis and CRISPR functional screens. PhD in Computational Biology, MIT.
Marcus Elliot
PartnerPartner at Basil Health Ventures since 2019, where his involvement on any device deal functions as a substantial de-risking of the regulatory pathway. Marcus leads regulatory strategy across the medical device and diagnostics portfolio — active board member at five portfolio companies. His judgment on FDA 510(k) and PMA submissions is the firm's single most differentiated capability in device investing. Previously 18 years at the FDA's Center for Devices and Radiological Health, managing submissions for novel diagnostics and therapeutic devices.
Dr. Nadia Vasquez
PrincipalPrincipal at Basil Health Ventures, leading early-stage sourcing in digital health and AI diagnostics. Nadia is the first call for pre-seed and seed-stage founders in these areas — she evaluates clinical validity from direct practice experience, which gives the firm a real edge in separating genuine clinical tools from tech dressed as medicine. Previously six years in emergency medicine after completing her MD at Johns Hopkins.